IN BRIEF 1: Traumakine
READY FOR SALE? IT HAS BEEN REMOVED FROM THE PIPE-LINE.
"Faron will revolutionize intensive care"
BUT: It is a MULTIFUNCTIONAL DRUG = potential.
Traumakine® was originally developed for the treatment of acute respiratory failure syndrome (ADRS). It was once statused as an ‘orphan’. It is currently being tested for intensive care for people infected with COVID. According to Faron, the patients participating in the test need little additional oxygen and no help from ventilators. Some of the subjects receive Traumakine and some receive cortisone treatment.
Acute Respiratory Distress Syndrome Treatment Market Size & Share Analysis -
The market exhibits moderate fragmentation. Medtronic, GE Healthcare, and Philips anchor mechanical ventilation while Hamilton Medical pioneers adaptive feedback. Faron Pharmaceuticals, Mesoblast, and Athersys fuel the immunomodulator pipeline. Partnerships proliferate, typified by Roche and Poseida Therapeutics aligning cell therapies with respiratory indications. Device makers collaborate with software firms to fuse ventilator metrics with cloud analytics
Traumakine® was once Faron’s lead drug candidate, but the new focus is on the development of bexmarilimab.
Two US DoD Grants:
- the use of intravenous interferon beta (Traumakine) for the prevention of ischemia-reperfusion injury in battlefield victims when using a lifesaving torniquet for the prevention of excessive blood loss. The Study is named Resuscitation by Endothelial Stabilization and Targeted Oxygen Rescue (RESTOR) Platform for Battlefield Applications.
- Traumakine was highly effective for limb salvage and prevention of systemic inflammation and organ damage when given at the time of placing the torniquet, but not when given later. In the current setting Traumakine will be investigated when given as a preventative treatment prior to placing the torniquet.
Traumakine could be used to control cytokine release caused by immunoterapies and infections (cytokine release symptoms (CRS) ("long covid")... cytokine storm).
https://synapse.patsnap.com/article/what-is-traumakine-used-for?
The primary indication for Traumakine is the treatment of acute respiratory distress syndrome (ARDS). ARDS is a life-threatening condition that can arise from various causes, including pneumonia, sepsis, trauma, and more recently, severe cases of COVID-19. The hallmark of ARDS is rapid-onset respiratory failure, necessitating prompt and aggressive medical intervention. Patients with ARDS often require mechanical ventilation and intensive care to support their breathing and manage the underlying causes of the condition.
Traumakine's mechanism of action is centered around its ability to modulate the body's immune response. At its core, Traumakine leverages the anti-inflammatory properties of interferon-beta. Interferon-beta is a cytokine, a category of proteins involved in cell signaling, which plays a critical role in the body's immune response. In the context of ARDS, an overactive immune response can lead to significant lung damage, as the body's own defenses inadvertently attack lung tissue, causing inflammation and fluid accumulation.
When administered, Traumakine aims to restore balance to the immune response. By introducing interferon-beta, the drug helps downregulate the production of pro-inflammatory cytokines while promoting the production of anti-inflammatory agents. This dual action can potentially reduce the severity of the inflammatory response, thereby minimizing lung damage and improving patient outcomes. The precise modulation of the immune system is a delicate task, but the targeted action of interferon-beta holds promise in achieving this balance.
Comment:
A multifunction project, left aside - ready for markets? 5...10 mrd$? Solving all the needs of the company...
My former posts:
https://faronmave.blogspot.com/2026/01/traumakine-strateginen-laake.html
https://faronmave.blogspot.com/2026/01/traumakine-2.html
Kommentit
Lähetä kommentti